Literature DB >> 18339190

Diagnosis and management of respiratory involvement in Hunter syndrome.

Wolfgang Kamin1.   

Abstract

UNLABELLED: Respiratory problems are frequently encountered by patients with Hunter syndrome and contribute to the premature mortality seen in individuals with the disease. Progressive deposition of glycosaminoglycans in the soft tissue of the throat and trachea is thought to be responsible for the airway dysfunction and obstruction, which characterize the syndrome. Other physical characteristics, including abnormalities in the shape and structure of the ribs, abdominal organ enlargement, short neck and immobile jaw, further contribute to the respiratory problems. New measurement systems specifically tailored to paediatric patients now allow clinicians to follow the progressive deterioration of lung function, which was previously challenging in this population. Sleep apnoea is another common feature of Hunter syndrome, which can lead to a reduction in oxygen saturation of the blood and severely disrupts sleep. In our clinic, continuous positive airway pressure (CPAP), in which inspired air at elevated pressure is delivered through a specially designed mask, has proved to be effective for reducing sleep apnoea in patients with Hunter syndrome. As a consequence of the anatomical and pathological changes in the upper airways of patients with Hunter syndrome, general anaesthesia - especially intubation - is a difficult and potentially high-risk procedure. Consequently, such procedures should be performed by an anaesthetist - ideally accompanied by a paediatric pneumologist/intensivist - with experience in managing patients with Hunter syndrome.
CONCLUSION: Respiratory abnormalities are a major contributor to the premature mortality seen in Hunter syndrome. Treatment of these respiratory problems requires the careful attention of clinicians skilled in the recognition, diagnosis, management and treatment of Hunter syndrome.

Entities:  

Mesh:

Year:  2008        PMID: 18339190     DOI: 10.1111/j.1651-2227.2008.00650.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  16 in total

1.  Neonatal pulmonary interstitial glycogenosis in a patient with Hunter syndrome.

Authors:  Koenraad Smets; Sabine Van Daele
Journal:  Eur J Pediatr       Date:  2011-03-22       Impact factor: 3.183

2.  Successful noninvasive ventilation and enzyme replacement therapy in an adult patient with morbus hunter.

Authors:  M Westhoff; P Litterst
Journal:  JIMD Rep       Date:  2011-12-16

3.  Mucopolysaccharidosis Type II and the G374sp Mutation.

Authors:  E Martínez-Quintana; F Rodríguez-González
Journal:  Mol Syndromol       Date:  2013-02-13

4.  Surgical consideration in Hunter syndrome: a case of hydrocephalus and a case of epidural hematoma.

Authors:  Jin Li; Xinyan Zhang; Tao Jiang; Chunde Li
Journal:  Childs Nerv Syst       Date:  2018-11-15       Impact factor: 1.475

5.  Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey.

Authors:  Bianca Link; Louise Lapagesse de Camargo Pinto; Roberto Giugliani; James Edmond Wraith; Nathalie Guffon; Elke Eich; Michael Beck
Journal:  Orthop Rev (Pavia)       Date:  2010-09-23

6.  Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.

Authors:  Maurizio Scarpa; Zsuzsanna Almássy; Michael Beck; Olaf Bodamer; Iain A Bruce; Linda De Meirleir; Nathalie Guffon; Encarna Guillén-Navarro; Pauline Hensman; Simon Jones; Wolfgang Kamin; Christoph Kampmann; Christina Lampe; Christine A Lavery; Elisa Leão Teles; Bianca Link; Allan M Lund; Gunilla Malm; Susanne Pitz; Michael Rothera; Catherine Stewart; Anna Tylki-Szymańska; Ans van der Ploeg; Robert Walker; Jiri Zeman; James E Wraith
Journal:  Orphanet J Rare Dis       Date:  2011-11-07       Impact factor: 4.123

7.  Management of difficult airway with laryngeal mask in a child with mucopolysaccharidosis and mitral regurgitation: a case report.

Authors:  Mohsen Ziyaeifard; Rasoul Azarfarin; Rasoul Ferasatkish; Majid Dashti
Journal:  Res Cardiovasc Med       Date:  2014-04-01

Review 8.  Anaesthesia and airway management in mucopolysaccharidosis.

Authors:  Robert Walker; Kumar G Belani; Elizabeth A Braunlin; Iain A Bruce; Henrik Hack; Paul R Harmatz; Simon Jones; Richard Rowe; Guirish A Solanki; Barbara Valdemarsson
Journal:  J Inherit Metab Dis       Date:  2012-11-30       Impact factor: 4.982

Review 9.  Respiratory and sleep disorders in mucopolysaccharidosis.

Authors:  Kenneth I Berger; Simone C Fagondes; Roberto Giugliani; Karen A Hardy; Kuo Sheng Lee; Ciarán McArdle; Maurizio Scarpa; Martin J Tobin; Susan A Ward; David M Rapoport
Journal:  J Inherit Metab Dis       Date:  2012-11-15       Impact factor: 4.982

10.  Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome).

Authors:  Molly Stapleton; Francyne Kubaski; Robert W Mason; Hiromasa Yabe; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Expert Opin Orphan Drugs       Date:  2017-03-08       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.